Metaba — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Metaba is an early-stage biotech targeting the global antimicrobial resistance (AMR) crisis with a novel oxysterol-based antibiotic platform. Originating from tuberculosis research, the company has expanded its scope to target other drug-resistant bacteria through hypothesis-driven metabolomic strategies. It is in the preclinical stage, building a leadership team with strong scientific and financial expertise, and actively engaging in partnerships and funding competitions to advance its pipeline.

Infectious DiseasesAntimicrobial ResistanceTuberculosis

Technology Platform

Hypothesis-driven metabolomic platform focused on discovering and optimizing semi-synthetic, orally bioavailable oxysterol-based antimicrobial compounds, supported by a computational drug discovery engine using molecular modeling, dynamics, and machine learning for hit identification and lead optimization.

Opportunities

The massive and growing global health crisis of antimicrobial resistance (AMR) creates a urgent need for novel antibiotic classes, attracting attention from global health agencies and potential partners.

Metaba's initial focus on Tuberculosis, a WHO-priority disease, offers potential pathways for accelerated regulatory review and funding from non-dilutive global health sources.

Risk Factors

High scientific risk associated with the novel oxysterol mechanism of action and the inherent failure rate of preclinical drug development.

Significant funding risk as a private, preclinical company in the challenging antibiotic development sector, where commercial returns are often perceived as limited.

Competitive Landscape

The competitive landscape for novel antibiotics is intense but characterized by a sparse pipeline of truly new mechanistic classes. Metaba competes with other biotechs and large pharma developing next-generation antibiotics, but its oxysterol platform represents a distinct and potentially first-in-class approach. Success will depend on demonstrating superior efficacy, safety, or resistance profiles compared to existing and pipeline treatments.

More companies in Small Molecule Drugs →More companies in United States →